‘Unusual’ for GLP-1 to not be listed: Lilly boss

The world’s largest pharmaceutical company said its weight loss and diabetes medicine belongs on the PBS at “a fair price”, as health minister indicates negotiations with companies will continue Discussions on pricing between Eli Lilly and the Australian Government to have glucagon-like peptide-1 (GLP-1) receptor agonist Mounjaro listed were not “close enough to bridge”, the